Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
  1. Home
  2. ETF
  3. KAPA
KAPA logo

KAPA

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewTechnicalNews
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

KAPA News

Kairos Pharma Acquires CL-273 to Expand Oncology Pipeline

Mar 02 2026Newsfilter

Significant Milestones in Biotech Sector This Week

Feb 27 2026NASDAQ.COM

Kairos Pharma to Acquire Oncology Assets from Celyn Therapeutics

Feb 27 2026NASDAQ.COM

Kairos Pharma Wins 2025 Clinical Trials Arena R&D Award for Advanced Prostate Cancer

Dec 17 2025Businesswire

D. Boral Capital Reiterates Buy Rating on Kairos Pharma with $9 Price Target Intact

Nov 04 2025Benzinga

D. Boral Capital Upholds Buy Rating for Kairos Pharma (KAPA)

Oct 21 2025NASDAQ.COM

Kairos Pharma Discusses Phase 2 Trial Results of ENV-105 for Advanced Prostate Cancer at ESMO Conference

Oct 20 2025Newsfilter

D. Boral Capital Reiterates Buy Rating on Kairos Pharma with $9 Price Target Intact

Oct 07 2025Benzinga

FedEx Shares Rise 5%; Check Out 20 Stocks Making Moves in Premarket Trading

Sep 19 2025Benzinga

Kairos Pharma to Host Virtual KOL Event Discussing Interim Efficacy Results of ENV105 in Advanced Prostate Cancer

Sep 11 2025Newsfilter

Carisma Therapeutics Shares Surge 133%; Check Out 20 Stocks Making Moves in Premarket Trading

Sep 02 2025Benzinga

5 Biotech Stocks to Monitor Before Key Clinical Trial Results in September 2025

Aug 27 2025NASDAQ.COM

Why Data Storage Shares Are Trading Higher By 35%; Here Are 20 Stocks Moving Premarket

Jul 16 2025Benzinga

Why Is Kairos Pharma Stock Surging On Tuesday?

Jul 15 2025Benzinga

Morning News Wrap-Up: Tuesday’s Biggest Stock Market Stories!

Jul 15 2025TipRanks

Nasdaq Gains Over 100 Points; Wells Fargo Earnings Top Views

Jul 15 2025Benzinga